Sat, Jul 26, 2014, 5:38 AM EDT - U.S. Markets closed

Recent

% | $
Click the to save as a favorite.

Exelixis, Inc. Message Board

  • wilderguide wilderguide Apr 16, 2013 7:30 PM Flag

    CTC 3rd generation iChip platform significant improvement

    $$$$
    News release from Mass General Hospital dated 4/3/13...
    "The new system was able to process blood samples at the extremely rapid rate of 10 million cells per second, handling a tube of blood in less than an hour. Both the mode of sorting out tagged CTCs, called tumor-antigen-dependent, and the technique that depletes white blood cells, called tumor-antigen-independent, recovered more than 80 percent of tumor cells from different types of cancer that had been added to blood samples. Comparison of the antigen-dependent-mode CTC-iChip with existing commercial technology for processing blood samples from patients with prostate, breast, pancreatic, colorectal and lung cancer showed the CTC-iChip to be more sensitive at detecting low levels of CTCs."
    GLTA

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • "In the antigen-independent mode, the CTC-iChip successfully identified CTCs from several types of cancers that had lost or never had the epithelial marker, including triple-negative breast cancer and melanoma."

      Big improvement. This system is not dependent on specific antigen presentation in order to detect CTC's. If a particular cancer lacks the target antigen or CTC's have undergone mesenchymal transition, the existing CellSearch system will miss them. I see many uses for the CTC technology. Early cancer detection with a simple blood test, genetic typing without a biopsy, diagnosis of progression, use as a surrogate endpoint in clinical trials, when properly validated this is a very promising technology.

 
EXEL
4.19-0.02(-0.48%)Jul 25 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.